Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2013

Conditions

Mild Cognitive ImpairmentAlzheimer's Disease

Interventions

DRUG

EVP-0962

Arms: 1,2,3,4

DRUG

Placebo

Arm 5

Trial Locations (1)

Glendale Adventist Medical Center, Glendale